Jo Howard

List of Publications by Year in descending order

40 papers	2,165 citations	430874 18 h-index	289244 40 g-index
43 all docs	43 docs citations	43 times ranked	1664 citing authors

#	Article	IF	Citations
1	Expanded eligibility for emerging therapies in sickle cell disease in the <scp>UK</scp> â€“ crizanlizumab and voxelotor. British Journal of Haematology, 2022, , .	2.5	1
2	Perinatal outcomes in women with sickle cell disease: a matched cohort study from London, UK. British Journal of Haematology, 2022, 196, 1069-1075.	2.5	6
3	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	4.6	61
4	Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. British Journal of Haematology, 2021, 194, 980-995.	2.5	28
5	Biopsychosocial Predictors of Quality of Life in Paediatric Patients With Sickle Cell Disease. Frontiers in Psychology, 2021, 12, 681137.	2.1	13
6	Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion. PLoS ONE, 2020, 15, e0236998.	2.5	12
7	Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial. Trials, 2020, 21, 347.	1.6	12
8	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	5.2	241
9	An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood, 2020, 136, 19-20.	1.4	4
10	Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients. Blood, 2020, 136, 29-30.	1.4	1
11	Prevention of Morbidity in Sickle Cell Disease (POMS2a)â€”overnight auto-adjusting continuous positive airway pressure compared with nocturnal oxygen therapy: a randomised crossover pilot study examining patient preference and safety in adults and children. Trials, 2019, 20, 442.	1.6	8
12	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
13	<scp>PF</scp>â€04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placeboâ€Controlled Study. Clinical and Translational Science, 2019, 12, 180-188.	3.1	25
14	A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood, 2019, 133, 1865-1875.	1.4	84
15	Maternal sickle cell disease and twin pregnancy: a case series and review of the literature. Hematology, 2019, 24, 148-158.	1.5	6
16	How I manage red cell transfusions in patients with sickle cell disease. British Journal of Haematology, 2018, 180, 607-617.	2.5	23
17	How I treat the older adult with sickle cell disease. Blood, 2018, 132, 1750-1760.	1.4	31
18	Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. British Journal of Haematology, 2018, 181, 460-475.	2.5	59

#	Article	IF	Citations
19	The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thrombosis Research, 2017, 158, 113-120.	1.7	6
20	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers. Blood, 2017, 130, 974-974.	1.4	23
21	Sickle cell disease: when and how to transfuse. Hematology American Society of Hematology Education Program, 2016, 2016, 625-631.	2.5	104
22	Mildly raised tricuspid regurgitant velocity 2.5â€“3.0â€‰m/s in pregnant women with sickle cell disease is not associated with poor obstetric outcome â€“ An observational cross-sectional study. Obstetric Medicine, 2016, 9, 160-163.	1.1	5
23	Cementless Total HIP Replacements in Sickle Cell Disease. HIP International, 2016, 26, 186-192.	1.7	19
24	Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood, 2015, 125, 3316-3325.	1.4	167
25	Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. Trials, 2015, 16, 376.	1.6	10
26	Pregnancy outcome in patients with sickle cell disease in the <scp>UK</scp> â€“ a national cohort study comparing sickle cell anaemia (<scp>H</scp>b<scp>SS</scp>) with <scp>H</scp>b<scp>SC</scp> disease. British Journal of Haematology, 2015, 169, 129-137.	2.5	83
27	Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature. Transfusion Medicine Reviews, 2015, 29, 220-230.	2.0	46
28	Guideline on the management of acute chest syndrome in sickle cell disease. British Journal of Haematology, 2015, 169, 492-505.	2.5	138
29	Costâ€effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the <scp>TAPS</scp> trial. European Journal of Haematology, 2014, 92, 249-255.	2.2	10
30	Evaluation of the validity of Hb A2and mean corpuscular haemoglobin action values in antenatal screening for beta thalassaemia carriers in England. British Journal of Haematology, 2014, 166, 607-611.	2.5	2
31	A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thrombosis Research, 2014, 133, 190-195.	1.7	27
32	Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease. British Journal of Haematology, 2013, 161, 455-456.	2.5	10
33	The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet, The, 2013, 381, 930-938.	13.7	209
34	Sickle cell disease in pregnancy. Obstetrics, Gynaecology and Reproductive Medicine, 2012, 22, 254-263.	0.3	3
35	The obstetric management of sickle cell disease. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 25-36.	2.8	236
36	Sickle Cell/Î²0-Thalassemia Associated With the 1393 bp Deletion Can be Associated With a Severe Phenotype. Hemoglobin, 2011, 35, 406-410.	0.8	4

#	Article	IF	Citations
37	Pain management and quality of life in sickle cell disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 347-352.	1.4	11
38	Prevalence of Nocturnal Hypoxia and Its Association with Disease Severity in Adults with Sickle Cell Disease.. Blood, 2009, 114, 261-261.	1.4	16
39	Measurement of Disease Severity in Patients with Sickle Cell Disease: A Systematic Review.. Blood, 2007, 110, 2250-2250.	1.4	9
40	Acute painful sickle cell crisis. , 0, , 601-604.		0